Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SVRE vs BBLG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BBLG Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–0 Matrix Metrics)

BBLG Overall Winner 6-Pillar Tally: SVRE 2 – 2 BBLG (2 Tie) Matrix Metrics: SVRE 0 – 5 BBLG

As of Nov 17, 2026, Bone Biologics Corp (BBLG) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). SVRE carries a Unified Composite Score of 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin), whereas BBLG carries 45.5/100 (HOLD) at $0.31 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SVRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SVRE vs BBLG
SVRE NASDAQ
SaverOne 2014 Ltd. American Depositary Shares
Services-Computer Programming Services
$0.43
-1.46% 1D
Market Cap $1.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 0.49β · 190% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.4%), weak momentum, RSI 28
RSI-14: 28.4 · SMA20: $0.89 · SMA50: $1.47
BBLG NASDAQ Head-to-Head Winner
Bone Biologics Corp Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.31
+5.78% 1D
Market Cap $1.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.99β · 102% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 50.0 Mom 84.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.0%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $0.37 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (SVRE 2 – 2 BBLG)

Columns: Metric · SVRE · BBLG
1. Valuation Multiples SVRE
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.6x N/M
2. Growth & Scale BBLG
Revenue Growth (YoY) -63.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.0M N/A
Market Cap $1.1M $1.1M
3. Profitability & Quality Tie
Gross Margin -41.1% N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -151.1% -47.5%
4. Balance Sheet & Cash Flow BBLG
Cash Generation (TTM) -$34M EBITDA -$2.6M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.00 Book/Sh · -151.1% ROE $1.76 Book/Sh · -47.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SVRE
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Scientific & Technical Instruments Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SVRE (0) vs BBLG (5)
Institutional Metric SVRE BBLG Criterion Row Edge
Market Capitalization
Scale
$1.1M $1.1M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-63.0% +0.0% Higher Growth BBLG
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-151.1% -47.5% Higher ROE BBLG
52-Week Range Position
Momentum
0% ($0–$6) 2% ($0–$2) Stronger Trend BBLG
Beta / 30D Volatility
Risk Regime
0.49β · 190% Vol 0.99β · 102% Vol Lower Realized Risk BBLG
Unified Institutional Score
Composite Signal
39.3 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite BBLG
Trailing 12M Revenue (USD)
Operating Scale
$2.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-41.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$34M EBITDA ($0.00 Book/Sh · -151.1% ROE) -$2.6M ($1.76 Book/Sh · -47.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BBLG +52.06 pp
SVRE: -76.25% · BBLG: -24.19%
3M Horizon BBLG +33.69 pp
SVRE: -85.08% · BBLG: -51.39%
6M Horizon BBLG +14.25 pp
SVRE: -89.55% · BBLG: -75.3%
1Y Horizon SVRE +23.89 pp
SVRE: -56.66% · BBLG: -80.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SVRE vs BBLG. Trailing 12-month operating profitability (SVRE 0.0% vs BBLG 0.0%) and valuation multiples (SVRE N/M vs BBLG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SVRE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.0M
Gross Margin-41.1%
Op. Margin0.0%
ROE / Fwd P/E-151.1% · N/M
BBLG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-47.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SVRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SVRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BBLG BREAKDOWN
104d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BBLG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SVRE Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $1.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BBLG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SVRE vs BBLG Key Questions & Quantitative Answers

As of Nov 17, 2026, Bone Biologics Corp (BBLG) is the stronger overall head-to-head candidate over SaverOne 2014 Ltd. (SVRE) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). SVRE carries a Unified Composite Score of 39.3/100 (SELL) at $0.43 (N/M Forward P/E, 0.0% operating margin), whereas BBLG carries 45.5/100 (HOLD) at $0.31 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SVRE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile BBLG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BBLG leads the Growth & Scale pillar: SVRE posts -63.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (-41.1% gross margin, 0.0% operating margin), compared with BBLG at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SVRE generates $2.0M in USD-normalized revenue versus N/A for BBLG. In operating R&D and SG&A reinvestment, SVRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBLG.

SVRE screens cheaper on headline valuation multiples. SVRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (unreported EBITDA margin), whereas BBLG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SVRE (-151.1% ROE) versus BBLG (-47.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SVRE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 190% Vol realized risk). By comparison, BBLG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.99β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.